The Environment as a Variable to Calibrate Mouse Models of Human Disease

环境作为校准人类疾病小鼠模型的变量

• 批准号: 8577178
• 负责人: JOHN M ESSIGMANN
• 金额: $ 31.59万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8577178
• 关键词: Adolescent; Adult; Affect; Aflatoxin B1; Animal Model; Animals; Antioxidants; Applications Grants; Benzene; Carcinogens; Cell physiology; Cells; Chemicals; Complex; Consensus Sequence; DNA; DNA Adduction; DNA Damage; DNA Repair Pathway; DNA Sequence; DNA-Directed DNA Polymerase; Development; Diagnostic Neoplasm Staging; Disease; Drug resistance; Environment; Environmental Carcinogens; Event; Exposure to; Female; Frequencies; Gene Expression; Genes; Genetic; Genome; Genomics; Goals; Grant; Hepatitis B; Hepatocarcinogenesis; Human; Incidence; Inflammation; Intervention; Investigation; Liver; Liver neoplasms; Maintenance; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of liver; Malondialdehyde; Measures; Modeling; Modification; Mus; Mutagenesis; Mutagens; Mutation; Nodule; Normal Cell; Pathway interactions; Pattern; Phase; Phenotype; Predisposition; Primary carcinoma of the liver cells; Process; Production; Protocols documentation; Public Health; Recording of previous events; Risk; Risk Factors; Role; Source; Staging; Technology; Testing; Time Study; Tissues; Transgenes; Transgenic Organisms; Tumor Promoters; Tumor stage; Variant; Work; adduct; design; disorder prevention; environmental agent; environmental carcinogenesis; environmental chemical; human disease; male; mouse model; mutant; next generation sequencing; non-genetic; postnatal; premature; programs; public health relevance; radiation resistance; repaired; research study; sex; therapy design; tool; tumor; tumor progression; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): Exposure to genotoxic carcinogens via both external and internal environments increases risks for major human cancers. Such chemicals form covalent adducts with DNA, which are thought to create a complex program of genetic change acting as the initiating event in malignant transformation and contributing to subsequent tumor progression. Adducts can also disrupt formation or maintenance of normal genome modifications, altering gene expression in affected tissues. Factors that influence formation or repair of adducts are thus likely to be important determinants of human susceptibility to environmental carcinogenesis. We propose an approach to elucidate types of DNA damage and cellular processes responsible for genetic changes that transform normal cells to malignant ones. As a tool, our work focuses on aflatoxin B1 (AFB1), an established risk factor for human hepatocellular carcinoma that strongly elevates risk in synergy with hepatitis B virus infection. As in the human HCC incidence pattern, AFB1 is more potent in males than females, and animals of both sexes are more sensitive as juveniles than as adults. The hypothesis underlying our proposed work is that different quantitative features of mutagenesis (mutation frequencies) or qualitative features (mutational patterns) are determinants of the initiation and promotion phases of tum origenesis. The goal of our work is to characterize these quantitative and qualitative features and define their roles in modulating liver carcinogenesis. Experiments designed to test this hypothesis will employ a newly developed Duplex Sequencing protocol that enables the application of Next-generation sequencing platforms for mutational analysis. Mutation frequencies and spectra will be determined in selected genomic DNAs at stages throughout the tumorigenic process in a mouse model of AFB1-induced liver cancer. These analyses will enable us to determine whether a "mutator phenotype" is acquired during tumor development induced by AFB1, while providing a picture of its variation among different genes. Evidence of mutator phenotypes is seen in many advanced human tumors, and is increasingly considered as a possible source of premature-onset drug or radiation resistance. The types of mutations that we observe will provide hallmarks of the cellular processes that orchestrate the genetic changes during tumorigenesis. Our animal model is well suited to study the time of onset of a mutator phenotype and, of equal importance, for additional studies to investigate interventions that could delay tumor development and drug resistance.

描述（由申请人提供）：通过外部和内部环境暴露于遗传毒性致癌物会增加主要人类癌症的风险。这些化学物质与DNA形成共价加合物，这被认为是创造一个复杂的遗传变化程序，作为恶性转化的起始事件，并有助于随后的肿瘤进展。加合物还可以破坏正常基因组修饰的形成或维持，改变受影响组织中的基因表达。因此，影响加合物形成或修复的因素可能是人类对环境致癌作用易感性的重要决定因素。我们提出了一种方法来阐明导致正常细胞转化为恶性细胞的遗传变化的DNA损伤类型和细胞过程。作为一种工具，我们的工作重点是黄曲霉毒素B1（AFB1），一个确定的人类肝细胞癌的危险因素，强烈提高风险协同B型肝炎病毒感染。在人类HCC发病模式中，AFB1在雄性中比雌性更有效，并且两种性别的动物在幼年时比成年时更敏感。 我们所提出的工作的假设是，不同的诱变的定量特征（突变频率）或定性特征（突变模式）的启动和促进阶段的tumorigenesis的决定因素。我们工作的目标是描述这些定量和定性特征，并确定它们在调节肝癌发生中的作用。旨在验证这一假设的实验将采用新开发的双重测序方案，该方案能够应用下一代测序平台进行突变分析。在AFB1诱导的肝癌小鼠模型中，在整个肿瘤发生过程的各个阶段，将在选定的基因组DNA中确定突变频率和谱。这些分析将使我们能够确定在AFB1诱导的肿瘤发展过程中是否获得了“增变基因表型”，同时提供了不同基因之间的变异情况。在许多晚期人类肿瘤中发现了突变体表型的证据，并且越来越多地被认为是早发性药物或辐射抗性的可能来源。我们观察到的突变类型将提供在肿瘤发生期间协调遗传变化的细胞过程的标志。我们的动物模型非常适合研究突变表型的发病时间，同样重要的是，用于研究可能延迟肿瘤发展和耐药性的干预措施的额外研究。